TC
ALNY icon

TwinBeech Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

TwinBeech Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.31M Buy
+14,325
New +$4.32M 0.78% 44
2021
Q3 		– Sell
-17,916
Closed -$3.04M – 558
2021
Q2 		$3.04M Buy
+17,916
New +$2.62M 0.37% 86

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's ALNY Position: Q2 2026 in Review

TwinBeech Capital opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 14,325 shares worth $4.31M. The stake represents 0.78% of the portfolio and ranks #44 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in ALNY as recently as Q2 2021.

TwinBeech Capital first reported a position in ALNY in Q2 2021 and has held it in 2 quarters since. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • TwinBeech Capital held 14,325 shares of Alnylam Pharmaceuticals worth $4.31M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new TwinBeech Capital position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.78% of TwinBeech Capital's portfolio in Q2 2026, its #44 holding.
  • TwinBeech Capital first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.